Pharvaris (NASDAQ:PHVS) Rating Reiterated by Morgan Stanley

Morgan Stanley reaffirmed their overweight rating on shares of Pharvaris (NASDAQ:PHVS) in a report issued on Monday, Benzinga reports. The firm currently has a $34.00 target price on the stock.

A number of other equities analysts also recently commented on the stock. Wedbush restated an outperform rating and set a $35.00 price objective on shares of Pharvaris in a research report on Thursday, April 11th. JMP Securities upped their price objective on shares of Pharvaris from $49.00 to $50.00 and gave the stock a market outperform rating in a research report on Thursday, April 11th.

Pharvaris Trading Up 7.2 %

Shares of NASDAQ:PHVS opened at $22.77 on Monday. The firm has a fifty day moving average price of $23.55 and a 200 day moving average price of $23.32. Pharvaris has a 1-year low of $7.93 and a 1-year high of $33.00.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, April 10th. The company reported ($0.80) earnings per share for the quarter. On average, research analysts forecast that Pharvaris will post -2.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently bought and sold shares of PHVS. Hudson Bay Capital Management LP purchased a new position in shares of Pharvaris in the 3rd quarter valued at about $812,000. Walleye Capital LLC increased its holdings in shares of Pharvaris by 15.2% in the 3rd quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock valued at $1,691,000 after purchasing an additional 10,691 shares in the last quarter. Blackstone Inc. acquired a new stake in shares of Pharvaris during the 4th quarter worth about $2,805,000. Vivo Capital LLC acquired a new stake in shares of Pharvaris during the 4th quarter worth about $7,994,000. Finally, Commodore Capital LP acquired a new stake in shares of Pharvaris during the 4th quarter worth about $22,440,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).